Imetelstat Produces RBC Transfusion Independence in Lower-Risk Myelodysplastic Syndromes | ASH Clinical News | American Society of Hematology
Thomas R. Collins is a medical journalist based in West Palm Beach, Florida. The competitive telomerase inhibitor imetelstat produced prolonged independence from red blood cell (RBC) transfusions in a considerable number of patients with lower-risk myelodysplastic syndromes (MDS) who were ineligible for, had relapsed on, or been refractory to erythropoiesis-stimulating agents (ESA), according to new phase III findings published in The Lancet. The results from the IMerge trial point to the prospect of a